ENHA is trading at $2.91 (+6.20%) following renewed momentum from the launch of its Thor Protocol on the Live Enhanced platform.
- The clinician-supervised product stack is now officially available, driving significant after-hours strength and pre-market interest.
- The upward move represents a rebound from recent sharp declines, as traders react to the new product rollout rather than broader market catalysts.
- No other major corporate events or earnings reports were identified as contributors to the current price action.